What happened
PharmaResearch reported consolidated results for FY2025: revenue of US$370M (+53% year on year), operating profit of US$148M (+70% year on year) and net income of US$118M (+91.8% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$370M |
|---|---|
| Revenue vs a year earlier | +53% |
| Operating profit | US$148M |
| Net income | US$118M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-04, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260204900782 → open original filing |
Source: DART. Information only, not investment advice.